1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Pulmonary Arterial Hypertension (PAH) Treatment Market
2.2. Global Pulmonary Arterial Hypertension (PAH) Treatment Market, By Drug Class, 2024 (US$ Million)
2.3. Global Pulmonary Arterial Hypertension (PAH) Treatment Market, By Geography, 2024 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2024

3. Pulmonary Arterial Hypertension (PAH) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Pulmonary Arterial Hypertension (PAH) Treatment Market Vendors
3.2. Strategies Adopted by Pulmonary Arterial Hypertension (PAH) Treatment Market Vendors
3.3. Key Industry Strategies

4. Pulmonary Arterial Hypertension (PAH) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Pulmonary Arterial Hypertension (PAH) Treatment Market Value, 2023 - 2033, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2024 Versus 2033
5.3. Market Segmentation
5.3.1. Endothelin Receptor Antagonists (ERAs)
5.3.2. Vasodilators
5.3.3. Phosphodiesterase-5 (PDE-5) Inhibitors
5.3.4. Soluble Guanylate Cyclase (sGC) Stimulators
5.3.5. Calcium Channel Blockers (CCBs)
5.3.6. Others (anticoagulants, diuretics, and cardiac glycosides)


6. North America Pulmonary Arterial Hypertension (PAH) Treatment Market, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
6.3.Pulmonary Arterial Hypertension (PAH) Treatment Market: By Region, 2023-2033, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)

7. UK and European Union Pulmonary Arterial Hypertension (PAH) Treatment Market, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
7.3.Pulmonary Arterial Hypertension (PAH) Treatment Market: By Region, 2023-2033, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
7.3.1.5. France
7.3.1.5.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)

8. Asia Pacific Pulmonary Arterial Hypertension (PAH) Treatment Market, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
8.3.Pulmonary Arterial Hypertension (PAH) Treatment Market: By Region, 2023-2033, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
8.3.1.3. India
8.3.1.3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)

9. Latin America Pulmonary Arterial Hypertension (PAH) Treatment Market, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
9.3.Pulmonary Arterial Hypertension (PAH) Treatment Market: By Region, 2023-2033, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)

10. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Treatment Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
10.3.Pulmonary Arterial Hypertension (PAH) Treatment Market: By Region, 2023-2033, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market: By Drug Class, 2023-2033, USD (Million)

11. Company Profile
11.1. GlaxoSmithKline plc
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Gilead Sciences, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Novartis International AG
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Bayer AG
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Merck KGaA
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Bristol-Myers Squibb Company
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. United Therapeutics Corporation
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Actelion Pharmaceuticals Ltd
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Reata Pharmaceuticals, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Toray Industries, Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Liquidia Technologies, Inc.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Nuventra Pharma Sciences
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives